Vestal Point Capital, LP: summary

Vestal Point Capital, LP reported 68 positions with a reported value of $4.28B in its 13F for Q2 2026. Compared with Q1 2026: 11 new positions, 33 exited.

Top positions

• BioMarin Pharmaceutical Inc
• NEUROCRINE BIOSCIENCES INC COM
• ABIVAX SA SPONSORED ADS
• UNITED THERAPEUTICS CORP DEL COM
• Enliven Therapeutics Inc
• Nurix Therapeutics Inc
• Bicara Therapeutics Inc
• Taysha Gene Therapies Inc
• ARROWHEAD PHARMACEUTICALS INC COM
• ABBOTT LABORATORIES COM